Compare KKR & Co Inc (KKR) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KKR & Co Inc vs Sanofi SA — how do they compare? KKR & Co Inc trades at $97.26 (market cap $87.07B), while Sanofi SA trades at $43.88 (market cap $104.83B). The key difference: Sanofi SA is the larger of the two by market cap, and Sanofi SA pays the higher dividend (5.5%). Which is the better fit depends on your goals.
| KKR | SNY | |
|---|---|---|
Market Cap | $87.07B | $104.83B |
Sector | Financials | Health |
52-Week High | $152.16 | $52.34 |
52-Week Low | $83.88 | $41.33 |
Enterprise Value | $12.59B | $121.32B |
Dividend Yield | 0.77% | 5.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KKR trades at $96.72, down 4.19% over 24 hours, with a bullish technical signal from moving averages but overbought RSI readings. The company reported Q1 2026 EPS of $1.39, beating estimates, and maintains strong analyst support with 24 buy ratings. Recent developments include a $1.3 billion renewable energy joint venture in South Korea and the acquisition of EDF Power Solutions' North American operations for $4.2 billion, highlighting strategic expansion.
The outlook for KKR is positive, supported by robust deal activity and a favorable analyst consensus price target of $124.33. Key risks include execution of large acquisitions and market sensitivity to interest rate changes. Revenue is projected to grow to $20.4 billion in 2026, with net income margin improving to 14.51%, offering potential upside if operational targets are met.
SNY trades at $43.97, down 1.55% today, with a bullish technical signal supported by moving averages. The company reported strong Q1 2026 earnings of $1.10 per share, beating expectations, and maintains robust profitability with a 71.92% gross margin. Recent FDA approval for Sarclisa's subcutaneous formulation and expanded AI research collaboration with Aqemia highlight ongoing innovation. Cash flow from operations remains healthy at $10.75 billion for 2025, though net cash flow is minimal at $49 million.
SNY presents a balanced investment case with solid fundamentals and analyst support (44% buy ratings), but faces risks from EU antitrust probes and patent expiration concerns for key drug Dupixent. Valuation metrics appear reasonable with P/E of 19.81 and P/B of 1.29. The stock's outlook depends on successful drug pipeline execution and navigating regulatory challenges, with current price levels offering stability near support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About KKR & Co Inc
KKR is one of the world's largest alternative asset managers, with $490.7 billion in total assets under management, including $384.5 billion in fee-earning AUM, at the end of June 2022. The company has two core segments: asset management (which includes private markets--private equity, credit, infrastructure, energy and real estate--and public markets--primarily credit and hedge/investment fund platforms) and insurance (following the February 2021 purchase of a 61.5% economic stake in Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance). On the asset management side, private markets account for 50% of fee-earning AUM and 70% of base management fees, while public markets account for 50% and 30%, respectively.
Read more on KKR →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
